BCR and cancer: In our study of poor versus optimal responders, 10/16 patients (62%) with BCR::ABL1 mutations at BP who were sequenced at prior time points, had cancer gene variants that predated the BCR::ABL1 mutations [40], suggesting that cancer gene variants may predispose the leukemic clone to acquire BCR::ABL1 mutations.